Increasing Your Wegovy Dose: What Actually Happens and When

The moment you realise the starter dose wasn't supposed to do much

A question our prescribers hear regularly is: "I've been on 0.25 mg for a month and I haven't lost much weight — is it working?" The honest answer is that 0.25 mg isn't meant to drive significant weight loss. It exists to settle your system into the medicine: to let your gut, your appetite signalling and your tolerance all adjust before the dose climbs. People sometimes feel let down by this, imagining they've been given a watered-down version. They haven't. The 0.25 mg period is part of the design, not a holding pattern.

Once your body has had that settling-in time, your prescriber will typically move you to 0.5 mg after around four weeks, then 1.0 mg, then 1.7 mg, and finally 2.4 mg, each step spaced about a month apart. The purpose of the spacing is clinical, not bureaucratic. Gastrointestinal side effects are most likely after a dose change, and four weeks gives them a chance to settle before the next increase. Rushing through steps tends to mean spending several weeks feeling consistently unwell, which helps nobody. You can read more about the full Wegovy dose schedule if you want a precise breakdown of each level.

Throughout this phase, the appetite-suppressing effect does genuinely strengthen as the dose rises. Semaglutide acts on GLP-1 receptors in the brain and gut, slowing how fast food leaves your stomach and reducing hunger signals. At higher doses, that signal is more sustained. Most people find the shift in appetite becomes noticeably clearer somewhere between 1.0 mg and 1.7 mg, though individual responses vary considerably.

What increasing your Wegovy dose actually does to appetite and weight loss

So what does increasing your Wegovy dose do, beyond moving a number up? Clinically, each step upward amplifies GLP-1 receptor activity. That translates into a longer feeling of fullness after meals, reduced interest in food between meals, and a slower gastric-emptying effect that means your stomach takes longer to process what you've eaten.

The STEP 1 trial (a 68-week study in adults without diabetes, published in the New England Journal of Medicine) found an average body-weight reduction of around 15% at the 2.4 mg maintenance dose alongside lifestyle changes. That figure comes from reaching and holding the full maintenance dose, not from the first few weeks at 0.25 mg. It illustrates why completing the escalation matters: the therapeutic benefit builds as the dose does. If you're curious whether higher doses reliably translate to greater results, there's a detailed answer to that specific question worth reading alongside this page.

The flip side is that side effects also tend to peak around each dose increase. Nausea and loose stools are most common in the first week or two after stepping up, usually easing as the body adjusts. Knowing this in advance makes a real difference, it's temporary discomfort, not a sign something has gone wrong. A fuller picture of what to watch for is covered in the side-effects guide specific to dose changes.

The 7.2 mg pen, and when the question of going further becomes relevant

For most people on Wegovy, 2.4 mg is the maintenance dose they'll stay on. In January 2026, the MHRA approved a higher 7.2 mg dose of semaglutide for Wegovy, initially supplied as three 2.4 mg pens per week. Then, on 14 April 2026, a dedicated single-dose 7.2 mg Wegovy pen was approved, a single weekly injection replacing the multi-pen arrangement. This option is for adults with a BMI of 30 or above only and is not available as a starting point; it follows completion of the standard escalation and requires a clinical assessment before any move to that level. According to the MHRA's announcement, trials at 7.2 mg showed around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide considerably.

Whether 7.2 mg is appropriate for someone already on 2.4 mg is a clinical conversation, not a self-referral. Dose availability at any given time is also confirmed at consultation rather than assumed. The right moment to explore it is with a prescriber who knows your history on the medicine.

What your prescriber looks for before approving the next step

A dose increase isn't automatic. Before moving you up, a clinician will typically consider how you've been tolerating the current dose, whether side effects have settled, and whether there are any new health changes that affect the picture. For people who've transferred from another provider, evidence of the current dose is required before a step up is approved, that's standard clinical practice, not a bureaucratic hurdle.

It's also worth knowing that if you experience a significant side-effect flare after stepping up, your prescriber may choose to hold the dose at the current level for longer before trying again, or in some cases to step back down temporarily. The patient guide on what to expect during a Wegovy dose increase goes into the practical detail of managing this period day to day.

For anyone weighing up the cost of staying on treatment through escalation, a useful reference is the Wegovy pricing page, which explains how private treatment is structured and what a single transparent price typically covers. If you'd like to talk through where you are in your dose journey, speaking to our prescribers is straightforward to arrange.